Protecting the World from Pertussis and Other Emerging Diseases
BioNet is a leading developer and manufacturer of vaccines, specializing in recombinant and mRNA-based solutions targeting respiratory diseases and other global public health challenges. With a proven track record in research, development, and biomanufacturing, BioNet has successfully advanced proprietary recombinant pertussis vaccines from early-stage innovation to licensure. The company currently distributes a portfolio of vaccines through an established global commercial network and continues to expand its operations across continents.
3 licensed
recombinant pertussis vaccines
200+ qualified and passionate individuals fueling vaccine innovation
25+ years’ experience in vaccines
20 clinical trials conducts
10+ mRNA candidates
New research boosts future whooping cough vaccines
Researchers at the University of Texas at Austin have discovered two human-derived antibodies, hu1B7 and hu11E6, that effectively neutralize pertussis toxin (PT) by targeting its most vulnerable regions. This breakthrough provides a structural blueprint for improving current acellular pertussis vaccines and developing next-generation formulations like PTgen, a genetically detoxified pertussis toxin. The findings not only support the use of PTgen in enhancing vaccine durability and efficacy but also highlight the potential of these antibodies as therapeutic tools, particularly for protecting infants who are most at risk from severe pertussis infection.
Latest News
BioNet wins BARDA patch forward prize for microneedle mRNA vaccine innovation
BioNet, a global leader in vaccine innovation, proudly announces its selection as a Concept Stage winner in the prestigious United States Biomedical Advanced Research and Development Authority (BARDA) Patch Forward Prize. Achieved in collaboration with LTS Lohmann Therapie-Systeme AG, this recognition underscores BioNet’s contributions to mRNA vaccine technologies and their transformative potential to improve global health.
New Discoveries
Skin patch delivery of a SARS-CoV-2 spike DNA vaccine produces broad neutralising antibody responses
Infant responses to primary immunization following vaccination in pregnancy with varying doses of recombinant acellular pertussis vaccine alone or combined with tetanus-diphtheria
